Delving into the Latest Updates on Shizuoka Cancer Center with Synapse

A prospective study on clinical indicators that affect the rate of weight loss in allogeneic hematopoietic stem cell transplantation - Prospective study on weight loss rate in allogeneic hematopoietic stem cell transplantation

开始日期2024-04-01

申办/合作机构

Shizuoka Cancer Center

JPRN-UMIN000052199 / RecruitingIIT

Perioperative Quality of Life Changes in Patients with Pancreaticoduodenectomy - Perioperative Quality of Life Changes in Patients with Pancreaticoduodenectomy

开始日期2023-09-11

申办/合作机构

Shizuoka Cancer Center

JPRN-UMIN000051145 / RecruitingIIT

A prospective observational study for the usefulness of Japan Esophageal Society Classification B2 for estimating cancer invasion depth in superficial esophageal squamous cell carcinomas - Japan BEES study

开始日期2023-05-29

申办/合作机构

Shizuoka Cancer Center

100 项与 Shizuoka Cancer Center 相关的临床结果

登录后查看更多信息

0 项与 Shizuoka Cancer Center 相关的专利（医药）

登录后查看更多信息

3,540

项与 Shizuoka Cancer Center 相关的文献（医药）

2024-12-01·Techniques in Coloproctology

Incidence and risk factors for perineal hernia after robotic abdominoperineal resection: a single-center, retrospective cohort study

Article

作者: Shiomi, A ; Hino, H ; Manabe, S ; Tanaka, Y ; Kagawa, H ; Kasai, S ; Yamaoka, Y ; Maeda, C ; Kinugasa, Y

BACKGROUNDPerineal hernia (PH) is a late complication of abdominoperineal resection (APR) that may compromise a patient's quality of life. The frequency and risk factors for PH after robotic APR adopting recent rectal cancer treatment strategies remain unclear.METHODSPatients who underwent robotic APR for rectal cancer between December 2011 and June 2022 were retrospectively examined. From July 2020, pelvic reinforcement procedures, such as robotic closure of the pelvic peritoneum and levator ani muscles, were performed as prophylactic procedures for PH whenever feasible. PH was diagnosed in patients with or without symptoms using computed tomography 1 year after surgery. We examined the frequency of PH, compared characteristics between patients with PH (PH+) and without PH (PH-), and identified risk factors for PH.RESULTSWe evaluated 142 patients, including 53 PH+ (37.3%) and 89 PH- (62.6%). PH+ had a significantly higher rate of preoperative chemoradiotherapy (26.4% versus 10.1%, p = 0.017) and a significantly lower rate of undergoing pelvic reinforcement procedures (1.9% versus 14.0%, p = 0.017). PH+ had a lower rate of lateral lymph node dissection (47.2% versus 61.8%, p = 0.115) and a shorter operative time (340 min versus 394 min, p = 0.110). According to multivariate analysis, the independent risk factors for PH were preoperative chemoradiotherapy, not undergoing lateral lymph node dissection, and not undergoing a pelvic reinforcement procedure.CONCLUSIONSPH after robotic APR for rectal cancer is not a rare complication under the recent treatment strategies for rectal cancer, and performing prophylactic procedures for PH should be considered.

2024-11-01·Annals of Oncology

Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY

Article

作者: Kataoka, K ; Kagawa, Y ; Kato, T ; Oki, E ; Takemasa, I ; Aleshin, A ; Taniguchi, H ; Kotani, D ; Yukami, H ; Akazawa, N ; Sharma, S ; Laliotis, G ; Mori, K ; Miyo, M ; Watanabe, J ; Bando, H ; Kotaka, M ; Kato, K ; Hirata, K ; Mishima, S ; Liu, M C ; Jurdi, A ; Yoshino, T ; Yokota, M ; Palsuledesai, C C ; Yamazaki, K ; Nakamura, Y ; Rabinowitz, M ; Ando, K

BACKGROUNDThe prognostic role of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection and its utility for postsurgical risk stratification has been reported in colorectal cancer. In this study, we explored the use of ctDNA-based MRD detection in patients with colorectal liver metastases (CLM), for whom the survival benefit of adjuvant chemotherapy (ACT) after surgical resection remains unclear.METHODSPatients with CLM without extrahepatic disease from the GALAXY study (UMIN000039205) were included. The disease-free survival (DFS) benefit of ACT was evaluated in MRD-positive and -negative groups after adjusting for age, gender, number, and size of liver metastases, RAS status, and previous history of oxaliplatin for primary cancer. ctDNA was detected using a personalized, tumor-informed 16-plex polymerase chain reaction-next-generation sequencing (mPCR-NGS) assay. ctDNA-based MRD status was evaluated 2-10 weeks after curative surgery, before the start of ACT.RESULTSAmong 6061 patients registered in GALAXY, 190 surgically resected CLM patients without any preoperative chemotherapy were included with a median follow-up of 24 months (1-48 months). ctDNA positivity in the MRD window was 32.1% (61/190). ACT was administered to 25.1% (48/190) of patients. In the MRD-positive group, 24-month DFS was higher for patients treated with ACT [33.3% versus not reached, adjusted hazard ratio (HR): 0.07, P < 0.0001]; whereas no benefit of ACT was seen in the MRD-negative group (24-month DFS: 72.3% versus 62.2%, adjusted HR: 0.68, P = 0.371). Multivariate analysis showed that the size of liver metastases (HR: 3.94, P = 0.031) was prognostic of DFS in the MRD-positive group. In the MRD-negative group, however, none of the clinicopathological factors were prognostic of DFS.CONCLUSIONSOur data suggest that ACT may offer notable clinical benefits in MRD-positive patients with CLM. MRD status-based risk stratification could be potentially incorporated in future clinical trials for CLM.

2024-11-01·Journal of Vascular and Interventional Radiology

Percutaneous Transesophageal Gastric Tube Placement Using Hydrodissection without Targeting Balloon

Letter

作者: Sato, Rui ; Aramaki, Takeshi ; Takeuchi, Yoshito ; Asahara, Kazuhisa ; Saiga, Atsushi

100 项与 Shizuoka Cancer Center 相关的药物交易

登录后查看更多信息

100 项与 Shizuoka Cancer Center 相关的转化医学

登录后查看更多信息